Ticlopidine Generics Postmarketing Safety Program Being Considered By FDA

FDA is considering requiring a postmarketing safety program for generic ticlopidine products. FDA's Office of Generic Drugs, Office of the Chief Counsel and Office of Drug Evaluation I are discussing options for ticlopidine postmarketing commitments. The safety program could include four or five essential elements.